AIVIS Inc., a leading AI-based pathology analysis company (CEO Daehong Lee), successfully participated in the 2025 Korean Society of Pathologists (KSP) Fall Conference, held from October 30 to 31, where it demonstrated its latest advancements in AI-powered digital pathology solutions. At the conference’s main session, the PIC Forum, Dr. Gyuyeong Kim, Chief Medical Officer (CMO) of AIVIS, delivered a presentation titled “Reproducibility Crisis in IHC Interpretation and How AI Can Solve It.” He emphasized that immunohistochemistry (IHC) tests such as HER2 and PD-L1, which are critical for determining treatment strategies, often suffer from inconsistent interpretations among pathologists — an issue that continues to challenge clinical practice. With the introduction of more granular classification criteria such as HER2-Ultralow, interpretive subjectivity and variability have become even more pronounced. As a key solution, Dr. Kim presented how AI-driven quantification can enhance both the accuracy and consistency of IHC interpretation. He also shared findings from a multicenter study involving 38 board-certified breast pathologists in Korea, which demonstrated that AI-assisted interpretation improved interobserver agreement, achieving statistically meaningful gains in diagnostic consistency. The full results will be presented at ESMO Asia 2025, to be held in Singapore this December. During the conference, AIVIS also held in-depth discussions with Philips Korea, Leica Biosystems, and Roche Diagnostics, exploring opportunities for collaboration in the rapidly growing HER2 diagnostics market. These meetings laid the groundwork for future global partnerships aimed at expanding access to advanced AI pathology tools. “Our presentation at the PIC Forum drew strong interest by providing concrete evidence of how AI can address real-world challenges faced by pathologists in IHC quantification,” said Dr. Kim. “Building on this momentum and the enthusiasm from both clinicians and global partners, AIVIS will continue to deliver trusted AI solutions that raise the standard of pathological diagnosis.”